The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL

Clinical trial NCT07548255 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07548255
Sponsor: Ruijin Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Intermediate-to-High-Risk Mantle Cell Lymphoma the Efficacy and Safety

Start date: 2026-04-20
Primary completion: 2029-03-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.